OP16
Anti-c-ErbB2/c-Neu (Ab-4) Mouse mAb (7.16.4)
liquid, clone 7.16.4, Calbiochem®
Synonyme(s) :
Anti-HER2, Anti-c-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
NACRES:
NA.43
UNSPSC Code:
12352203
Clone:
7.16.4, monoclonal
Species reactivity:
rat, human
Application:
Citations:
10
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Anti-c-ErbB2/c-Neu (Ab-4) Mouse mAb (7.16.4), liquid, clone 7.16.4, Calbiochem®
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
7.16.4, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
rat, human
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Frozen Sections (5 µg/mL,
Immunoblotting
Immunocytochemistry (5 µg/mL)
Immunoprecipitation (1 µg/mL,
Neutralization Studies (not recommended, )
isotype
IgG2a
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... ERBB2(2064)
Analysis Note
Negative Control
Fisher rat embryo cells
Fisher rat embryo cells
Positive Control
B104-1-1 cells
B104-1-1 cells
Application
Frozen Sections (5 g/ml, see application references)
Immunoblotting (see application references)
Immunocytochemistry (5 g/ml)
Immunoprecipitation (1 g/ml, see application references)
Neutralization Studies (not recommended, see application references)
Disclaimer
Toxicity: Standard Handling (A)
General description
Anti-c-ErbB2/c-Neu (Ab-4), mouse monoclonal, clone 7.16.4, recognizes ~185 kDa c-ErbB2 in overexpressing B104-1-1 cells. It is validated for WB, IP, ICC, frozen sections, & growth inhibition assay.
Purified mouse monoclonal antibody generated by immunizing C3H mice with the specified immunogen and fusing splenocytes with NS-1 mouse myeloma cells (see application references). Recognizes the ~185 kDa c-ErbB2/c-neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in overexpressing B104-1-1 cells.
Immunogen
B104-1-1 cells overexpressing rat c-ErbB2/c-Neu
Epitope: Within the extracellular domain
Human
Other Notes
Stains frozen tissue sections of rat cells overexpressing c-neu. Does not inhibit in vitro protein-tyrosine kinase activity, but it will inhibit in vivo growth of tumors overexpressing the neu oncogene (see application references). Does not cross-react with the EGF receptor. Antibody should be titrated for optimal results in individual systems.
Zhang, H., et al. 1999. Exp. Mol. Pathol.67, 15.
Peterson, N,C., and Greene, M.I., 1988. DNA Cell Biol.17, 1031.
Kokai, Y., et al. 1988. Proc. Natl. Acad. Sci. USA85, 5389.
Van De Vijver, M.J., et al. 1988. New Engl. J. Med.319, 1239.
DiFiore, P.P., et al. 1987. Science237, 178.
Kokai, Y., et al. 1987. Proc. Natl. Acad. Sci. USA84, 8498.
Slamon, D.J., et al. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Peterson, N,C., and Greene, M.I., 1988. DNA Cell Biol.17, 1031.
Kokai, Y., et al. 1988. Proc. Natl. Acad. Sci. USA85, 5389.
Van De Vijver, M.J., et al. 1988. New Engl. J. Med.319, 1239.
DiFiore, P.P., et al. 1987. Science237, 178.
Kokai, Y., et al. 1987. Proc. Natl. Acad. Sci. USA84, 8498.
Slamon, D.J., et al. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Classe de stockage
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Michela Lizier et al.
Oncotarget, 7(38), 60793-60806 (2016-08-27)
Cell fusion between neoplastic and normal cells has been suggested to play a role in the acquisition of a malignant phenotype. Several studies have pointed to the macrophage as the normal partner in this fusion, suggesting that the fused cells
Rebecca A Rozich et al.
Experimental and molecular pathology, 89(3), 248-259 (2010-07-27)
Cholangiocarcinoma, a severe form of biliary cancer, has a high mortality rate resulting partially from the advanced stage of disease at earliest diagnosis. A better understanding of the progressive molecular and cellular changes occurring during spontaneous cholangiocarcinogenesis is needed to
Shannon O'Connor et al.
Protein expression and purification, 67(1), 41-47 (2009-04-21)
Receptor tyrosine kinases (RTKs) are the second largest family of membrane receptors and play a key role in the regulation of vital cellular processes, such as control of cell growth, differentiation, metabolism, and migration. The production of whole-length RTKs in
Heather Gibson et al.
Oncoimmunology, 4(1), e984523-e984523 (2015-05-08)
The goal is to elucidate the immune modulating activity of an adenovirus (Adv) vector which showed therapeutic activity in human clinical trials. The oncolytic adenovirus (Adv/CD-TK) expressing two suicide genes was tested in two HER2/neu positive BALB/c mouse mammary tumor
Kristina W Thiel et al.
Nucleic acids research, 40(13), 6319-6337 (2012-04-03)
Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers.
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique